Events & Presentations
Upcoming Events
| Date | Event Details | Remind Me |
|---|---|---|
|
Aug 5, 2021 4:30 PM EDT
|
Arrowhead Pharmaceuticals 2021 Third Quarter Results
|
Archived Events
| Date | Event Details |
|---|---|
|
Oct 8, 2020 8:30 AM EDT
|
Arrowhead/Takeda Collaboration Call
Prepared Remarks 164.7 KB
|
|
Oct 6, 2020 1:30 PM EDT
|
Chardan Virtual 4th Annual Genetic Medicines Conference
Vince Anzalone, CFA, Arrowhead’s vice president and head of investor relations, will participate in a fireside chat presentation
|
|
Sep 15, 2020 2:00 PM EDT
|
Cantor Fitzgerald Global Healthcare Conference 2020
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
|
Sep 15, 2020 9:30 AM EDT
|
H.C. Wainwright 22nd Annual Global Investment Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
|
Sep 10, 2020 2:00 PM EDT
|
Baird's 2020 Global Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
|
Sep 9, 2020
|
Citi’s 15th Annual BioPharma Virtual Conference
|
|
Aug 29 - Sep 1, 2020
|
European Society of Cardiology (ESC) Congress 2020
ESC 2020 ARO-APOC3 645.8 KB
ESC 2020 ARO-ANG3 828 KB
Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects With Inherited Apolipoprotein C-3 Deficiency
Authors: Christian Schwabe, et al. Presenter: Christie M. Ballantyne Date and Time: August 31, 2020 at 10:50 CEST Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia Authors: Gerald F. Watts, et al. Date and Time: August 31, 2020 at 11:00 CEST |
|
Aug 27 - Aug 29, 2020
|
The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL)
View Presentation 716.9 KB
Title: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Authors: Edward Gane, et al. |
|
Aug 5, 2020 4:30 PM EDT
|
Arrowhead Pharmaceuticals 2020 Third Quarter Results
Prepared Remarks 178.7 KB
|
|
Jul 28, 2020 12:00 PM EDT
|
ARO-ENaC KOL Webinar
View Presentation 3.2 MB
|